Medivolve is not speculation should be trading on real reven We should get a news release tomorrow or the day after. Medivolve needs to update us on the partnership or deal with Biocorp. They are adding seven testing sites in testbeforeyougo.com. Deal can be profit-sharing, they buying testing kits from Medivolve plus paying a fee to use the platform or Biocorp getting paid per test and collection sites managing everything.
Sanaty IPS Columbian portfolio company adding the second location need to make public. Sanaty IPS are not only covid sites. Sanaty IPS are full-service medical clinics. Sanaty is authorized by the Columbian Ministry of Health to provide its services via telemedicine. QuestCap owns a 28% indirect equity interest in Sanaty IPS.
Medivolve is also working with RESAAS to offer covid-19 testing to over 400k realtors in the USA. RESAAS platform also selling testing kits online in the USA, Australia and Spain. As of now, we don't know these revenue numbers, but they are coming.
Once Medivolve updates us on all three revenue sources plus USD 2.1 million testing kits sold to Kinross Gold subsidiary. Investors will understand, Medivolve stock value is much higher compared to today. $10-$15 Revenue per month from collection sites with a projected 55% EBTIDA margin. The Medivolve stock deserves a much higher market cap than $80 million or so. Let alone revenue from RESAAS, Sanaty or other sales.
Now add up adding 100's more testing sites.
Joe Biden wants to invest $50 billion into testing.
Also, Biden wants to invite labs to help in vaccination, spending billions more.
Investors buying millions of shares for the last little while are not stupid. They know the real value for Medivolve and the progress MEDV making. If Anyone can see trading data, this is not retail buying. People buying are with deep pockets and know how to calculate the stock value.
Once retail finds out about this stock, it won't be a .14 cents gain. It probably trading over $2 with 46 testing sites. The more testing sites added, the higher the price goes.
Anyone day trading can make cents and lose out on dollars. Anyone analyzing trading data can see many people still shorting. If the upward trend takes MEDV into the .60's. There will be margin calls and covering, pushing the stock price even higher. So, people shorting or day traders should be careful if you don't want to miss out.
Of course, they might stall Medivolve in the .50's get all these week hands. Long term trend is Medivolve, going higher, not on speculation. $10-$15 revenue per month from collection sites with a projected 55% EBTIDA margin can take this stock into dollars.